Clinical trials: Familial Colorectal Cancer
Adenomatous Polyposis Coli
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
The purpose of this study is to determine whether sulindac and VSL#3 - inulin, either combined or alone, are effective in treating or preventing adenoma development in the ileal anal pouch in patients with familial adenomatous…
- Trial name
- NCT00319007
- Testing
- Sulindac (drug), VSL#3 (probiotic), Inulin (probiotic)
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Ulcerative Colitis, Familial Adenomatous Polyposis
Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch?
Total proctocolectomy with ileal pouch anal anastomosis is the first choice surgical operation for management of ulcerative colitis and familial adenomatous polyposis.
- Trial name
- NCT01173250
- Testing
- adding diverting ileostomy, omitting diverting ileostomy
- Sponsor
- Mansoura University
Familial Adenomatous Polyposes, Duodenal Polyposis
Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP)
Familial adenomatous polyposis (FAP) is an autosomal dominant genetic disorder that predisposes to a number or malignant disorders [1,2].
- Conditions
- Familial Adenomatous Polyposes, Duodenal Polyposis, Duodenal Cancer
- Trial name
- NCT03346980
- Testing
- Esophagogastroduodenoscopy
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Familial Adenomatous Polyposis (FAP)
Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis
This expanded access program provides 0.5 mg eRapa (encapsulated rapamycin) to patients with familial adenomatous polyposis (FAP) who have no satisfactory alternative treatment options and are not eligible to participate in a…
- Trial name
- eRapa-FAP (NCT07689942)
- Testing
- eRapa (encapsulated rapamycin)
- Sponsor
- Biodexa Pharmaceuticals
Colorectal Neoplasms
Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer
Two major genetic pathways leading to colorectal carcinoma can well be distinguished; the 'suppressor pathway', which is characterized by inactivation of tumor-suppressor genes and the 'mutator pathway', which is characterized by…
- Trial name
- NCT00220246
- Where
- Netherlands
- Volunteers
- 130 people
- Sponsor
- Radboud University Medical Center
Colorectal Cancer
Genetic Study of Patients and Families With a History of Colorectal Cancer
RATIONALE: Determination of genetic markers for colorectal cancer may help doctors to identify patients who are at risk. PURPOSE: Genetic testing study of patients and families with a history of colorectal cancer to identify…
- Trial name
- NCT00003648
- Testing
- DNA stability analysis, gene rearrangement analysis
- Where
- 12 sites in United States, Canada
- Volunteers
- 1,500 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Familial Adenomatous Polyposis
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Primary Objective: To determine whether celecoxib downregulates GATA-6 expression to upregulate 15-LOX-1 expression and induce apoptosis in human rectal tumors, researchers will measure GATA-6 and 15-LOX-1 expression, 13-S-HODE…
- Trial name
- NCT00503035
- Testing
- Celecoxib, Colonoscopy Biopsy
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- M.D. Anderson Cancer Center
Familial Adenomatous Polyposis, Colorectal Cancer
Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)
The goal of this research study is to test the first version of a website that will offer information and support for adolescents and young adults with FAP.
- Trial name
- NCT00525655
- Testing
- Web-Based Multimedia Intervention, Questionnaire
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Body Image Disorder
Prevention of Body Image Disorder by Nurse Intervention on the Patient and Family Prior to Breast and Colon Surgery
This is a non-blinded, randomized, controlled clinical trial consisting of 64 participants, which aims to assess the effectiveness of a nursing intervention for family members and patients prior to surgery to prevent body image…
- Trial name
- NCT03726801
- Testing
- HEALTH EDUCATION
- Where
- Spain
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Universidad Complutense de Madrid
Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP)
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)
RIPAF (Rete Italiana Poliposi Adenomatosa Familiare) is a national, multicenter observational registry designed to establish a coordinated Italian network for the management of Familial Adenomatous Polyposis (FAP) and related…
- Conditions
- Familial Adenomatous Polyposis (FAP), Attenuated Familial Adenomatous Polyposis (AFAP), MUTYH-Associated Polyposis (MAP), Non-APC/MUTYH Associated Polyposis (NAMP)
- Trial name
- RIPAF (NCT07461246)
- Where
- Italy
- Volunteers
- 1,500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Acute Leukemia, Adenomatous Polyposis
Familial Investigations of Childhood Cancer Predisposition
NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll.
- Conditions
- Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML
- Trial name
- SJFAMILY (NCT03050268)
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- St. Jude Children's Research Hospital
Adenomatous Polyposis Coli
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).
- Trial name
- CHIP (NCT00585312)
- Testing
- Celecoxib
- Where
- 42 sites in United States, Belgium and 12 more
- Volunteers
- 106 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Colorectal Cancer, Hereditary Non-polyposis Colon Cancer
Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
RATIONALE: Gathering medical and family history information from patients and family members may help doctors better understand hereditary colorectal cancer and hereditary polyposis syndrome and identify patients at high risk of…
- Conditions
- Colorectal Cancer, Hereditary Non-polyposis Colon Cancer, Precancerous Condition
- Trial name
- NCT00675636
- Testing
- study of socioeconomic and demographic variables, evaluation of cancer risk factors, study of high risk factors
- Where
- 3 sites in United States
- Volunteers
- 730 people
- Sponsor
- Vanderbilt University Medical Center
Ileal Pouch-Anal Anastomosis
Ileal Pouch-Anal Anastomosis Registry
Little is known about the factors that predispose patients to complications after an ileal pouch-anal anastomosis procedure (IPAA).
- Trial name
- IPAA (NCT01026480)
- Where
- United States
- Volunteers
- 936 people
- Sponsor
- Boston Medical Center
Colorectal Cancer
Genetic Study of Familial Factors in Patients With Colon Cancer
RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Clinical trial to study the cancer-related genes in patients who have colon cancer or…
- Trial name
- NCT00055848
- Testing
- cytogenetic analysis, gene mapping, microarray analysis
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Pediatric Reporting of Adult-Onset Genomic Results
The Investigators will conduct a longitudinal, mixed-methods cohort study to assess primary and secondary psychosocial outcomes among MyCode adolescent participants and their parents, and health behaviors of children who received…
- Conditions
- Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
- Trial name
- NCT03832985
- Testing
- Child(ren) receive an adult-onset result, Child(ren) received a pediatric-onset result, Control - Negative Result
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Geisinger Clinic
Colorectal Cancer, Precancerous Condition
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of celecoxib may keep polyps and colorectal cancer from forming in patients with familial adenomatous polyposis.
- Trial name
- NCT00685568
- Testing
- celecoxib
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
FAP-Familial Adenomatous Polyposis
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version
Colorectal cancer (CRC) is a leading cause for cancer related mortality in the western world with a lifetime risk of 6%. Etiology is complex, while genetic background significantly affects the risk.
- Trial name
- NCT02354560
- Testing
- Erythromycin
- Volunteers
- 15 people
- Sponsor
- michal roll
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis
- Trial name
- NCT00101270
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)